Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 12/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.36 |
| ▸ | TSHR | P16473 | 7/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13225322 | 0.74 | — | — | |
| SCHEMBL27953451 | 0.72 | — | — | |
| SCHEMBL16091003 | 0.69 | KDM4E (0.42) | CYP3A4CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL18649619 | 0.68 | CYP1A2 (0.40) | CYP3A4CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL11287500 | 0.68 | CYP3A4 (0.39) | CYP3A4CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL26958759 | 0.68 | CYP1A2 (0.39) | CYP3A4CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL29607566 | 0.65 | CRHR1 (0.39) | CYP3A4CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL31016065 | 0.65 | CYP1A2 (0.69) | CYP3A4CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL18708803 | 0.65 | CYP1A2 (0.34) | CYP3A4CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL23472180 | 0.64 | ALDH1A1 (0.43) | CYP3A4CYP1A2CYP2D6CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273136-A1 | NITROGEN-CONTAINING BRIDGED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-3317273-B1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3445357-B1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10450310-B2 | Bifunctional molecules for degradation of EGFR and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190106417-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| WO-2017004383-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106417-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | EGFR, ERBB2, ERBB3 | CYP3A4 4486/4885CYP1A2 3906/4885CYP2D6 4047/4885 |
| US-10450310-B2 | Bifunctional molecules for degradation of EGFR and methods of use | EGFR, ERBB2, ERBB3 | CYP3A4 4486/4885CYP1A2 3906/4885CYP2D6 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.